Stocklytics Platform
Altimmune
ALT62
$5.92arrow_drop_up13.46%$0.70
NASDAQ - As of Mar 15, 8:22 PM EDT Market Closed
ALT62

$5.92

arrow_drop_up13.46%
Key Stats
Open$5.39
Prev. Close$5.20
EPS-1.57
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$455.92M
PE Ratio-
LOWHIGH
Day Range5.22
6.03
52 Week Range2.09
14.84
Ratios
P/B Ratio3.56
Revenue-
Operating M. %-497320.00%
Earnings$0.00
Earnings Growth %-7.48%
EBITDA Margin %-
ROE %-59.86%
EPS-1.57
Fundamentals
RPS
Gross Profit
EBITDA
Total Debt
P/S Ratio
Enterprise to EBITDA
Profit Margin
ROA
Debt/Equity Ratio
Payout Ratio
Industry average yield
Last Dividend pay date
Dividend per share
Dividend yield forecast

Stock Analysis

Stock Performance

ALT-
US Tech-
US Market-

Altimmune (ALT) Statistics

Altimmune Inc (ALT) is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. With a market capitalization of $X, Altimmune has become a significant player in the healthcare sector. The company's valuation metrics including price to earnings ratio (P/E), price to sales ratio (P/S), and price to book ratio (P/B) reflect its potential for growth and profitability. ALT's current P/E ratio is XXXX, which indicates that investors are willing to pay more for each dollar of earnings. The P/S ratio of ALT is XXXX, suggesting that the market values the company's sales at a premium. ALT's P/B ratio is XXXX, indicating that the stock is trading at a higher price compared to its book value.
When analyzing the fundamentals of Altimmune Inc (ALT), it is important to consider factors such as revenue per share, enterprise to EBITDA, profit margin, total debt, and gross profit. The revenue per share of ALT is XXXX, demonstrating the company's ability to generate revenue on a per share basis. ALT's enterprise to EBITDA ratio is XXXX, indicating its financial efficiency and profitability. The profit margin of ALT is XXXX, indicating the percentage of each dollar of revenue that the company retains as profit. ALT's total debt is XXXX, representing the amount of money the company owes to creditors. Lastly, ALT's gross profit is XXXX, reflecting the company's profitability after deducting the cost of goods sold.
add Altimmune  to watchlist

Keep an eye on Altimmune

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the EBITDA of Altimmune (ALT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Altimmune (ALT) is -$102.9M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Altimmune (ALT) have?

Altimmune (ALT) has a total debt of $1.77M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$29.7M.
help

How has Altimmune (ALT) stock's performance compared to its sector and the market over the past year?

Over the past year, Altimmune (ALT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 21.28%, Altimmune has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.40%, it has fallen short of the market average. This comparison highlights Altimmune 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Altimmune (ALT) stock?

The PE ratio for Altimmune (ALT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Altimmune (ALT) stock?

The Earnings Per Share (EPS) for Altimmune (ALT), calculated on a diluted basis, is -$1.57. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Altimmune (ALT) stock?

The operating margin for Altimmune (ALT) is -497.32K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

Take Your Investments to a Whole New Level